T 细胞免疫疗法市场：依作用机制、产品类别、治疗类型、适应症分类 - 2025-2030 年全球预测

T细胞免疫治疗市场2023年估值为68.1亿美元，预计2024年将达到77.4亿美元，复合年增长率为14.12%，预计到2030年将达到171.7亿美元。

T细胞免疫疗法是癌症治疗的一种创新方法，重点是增强人体的免疫系统来对抗疾病。该方法涉及修改 T 细胞以有效识别和破坏癌细胞。由于化疗和放射线治疗等传统癌症治疗的限制和副作用，出现了对这种治疗的需求。这种治疗方法主要应用于血癌，但随着最近的技术创新，它也被应用于固体癌。主要最终使用者包括医院、癌症治疗中心和研究机构。癌症发病率的增加、基因编辑技术的进步以及 CAR-T 和 TCR-T 等治疗方法的成功推动了市场成长。政府和私人组织的财政支持也刺激了市场动态。新的机会在于同种异体疗法的开发，这些疗法有望降低成本并增加可及性。与生技公司的合作伙伴关係和研究合作可以帮助您创新并提高治疗方法效果，为您带来竞争优势。然而，高处理成本、复杂的製造流程和严格的监管要求等挑战可能会阻碍成长。此外，后勤方面的挑战，例如需要个人化治疗，也是一个主要限制。为了克服这些障碍，重要的是提高製造技术并专注于具有成本效益的方法。人们越来越需要透过研究来了解肿瘤微环境并提高 T 细胞特异性以减少意外的副作用。该市场充满活力，其特点是快速的技术创新、激烈的竞争和不断变化的监管环境。最佳创新领域包括开发针对更广泛肿瘤的下一代 T 细胞疗法以及提高现有疗法的安全性。透过专注于这些领域，公司可以抓住机会推进 T 细胞免疫疗法，并在这个快速发展的市场中实现显着成长和成功。

市场动态：揭示快速发展的 T 细胞免疫治疗市场的关键市场洞察

T 细胞免疫治疗市场正因供需的动态交互作用而发生转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

• 市场驱动因素
  • 癌症和自体免疫疾病的盛行率增加
  • 利用基于细胞的标靶治疗
  • 增加支持 T 细胞免疫疗法的研究和开发
• 市场限制因素
  • 治疗费用上涨
• 市场机会
  • 製药公司的商业化和资金筹措
  • 现成药品的吸引力
• 市场挑战
  • 神经毒性和细胞激素释放综合征

波特五力：驾驭 T 细胞免疫疗法市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 T 细胞免疫治疗市场的外部影响

外部宏观环境因素在塑造 T 细胞免疫治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解T细胞免疫治疗市场的竞争格局

T 细胞免疫治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵T细胞免疫治疗市场供应商绩效评估

FPNV定位矩阵是评估T细胞免疫疗法市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了 T 细胞免疫治疗市场的成功之路

T 细胞免疫治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

• 市场动态
  • 促进因素
    • 癌症和自体免疫疾病的增加
    • 使用基于细胞的标靶治疗
    • 在研发支持下增强 T 细胞免疫疗法
  • 抑制因素
    • 治疗费用上涨
  • 机会
    • 製药公司的商业化和资金筹措
    • 现有治疗方法的吸引力
  • 任务
    • 神经毒性和细胞激素释放综合征
• 市场区隔分析
• 波特五力分析
• PESTEL分析
  • 政治的
  • 经济
  • 社群
  • 技术的
  • 合法地
  • 环境

第六章依作用机转分類的 T 细胞免疫治疗市场

• 主动免疫治疗
• 被动免疫疗法

第七章 T 细胞免疫治疗市场（依产品类别）

• 双特异性抗体
• 细胞激素
• 单株抗体
• 溶瘤病毒疗法

第八章 按治疗类型分類的 T 细胞免疫治疗市场

• CAR-T
• TCR
• TIL

第九章 T 细胞免疫治疗市场（按适应症）

• B细胞恶性
• 肝癌
• 摄护腺癌
• 肾臟细胞癌

第十章美洲T细胞免疫治疗市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第十一章亚太T细胞免疫治疗市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第十二章 欧洲、中东和非洲T细胞免疫治疗市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第十三章竞争格局

• 2023 年市场占有率分析
• FPNV 定位矩阵，2023
• 竞争情境分析
• 战略分析和建议

公司名单

• Adaptimmune Therapeutics PLC
• Alaunos Therapeutics, Inc.
• Apac Biotech
• Atara Biotherapeutics, Inc.
• Autolus Therapeutics PLC
• bluebird bio, Inc.
• Bristol-Myers Squibb Company
• CARsgen Therapeutics Holdings Limited
• Cellectis SA
• Chimera Bioengineering
• Dendreon Pharmaceuticals LLC
• Eureka Therapeutics, Inc.
• Gilead Sciences, Inc.
• Green Cross Corporation
• Innovative Cellular Therapeutics
• Iovance Biotherapeutics, Inc.
• LAVA Therapeutics NV
• Lyell Immunopharma, Inc.
• Neogene Therapeutics, Inc.
• NeoTX Therapeutics Ltd.
• Novartis AG
• Oxford Vacmedix UK Limited
• Poseida Therapeutics, Inc.
• TScan Therapeutics, Inc.
• Xenetic Biosciences, Inc.

The T-Cell Immunotherapy Market was valued at USD 6.81 billion in 2023, expected to reach USD 7.74 billion in 2024, and is projected to grow at a CAGR of 14.12%, to USD 17.17 billion by 2030.

T-cell immunotherapy is a transformative approach in cancer treatment, focusing on enhancing the body's immune system to combat diseases. This method involves modifying T-cells to identify and destroy cancer cells efficiently. The necessity of this therapy arises due to the limitations and adverse effects of traditional cancer treatments like chemotherapy and radiation. Its application predominantly spans hematologic cancers, though recent innovations are expanding its use to solid tumors as well. Key end-users include hospitals, cancer treatment centers, and research institutes. Market growth is propelled by increasing cancer incidences, advancements in gene-editing technologies, and the success of therapies like CAR-T and TCR-T. Funding from government and private entities also stimulates market dynamics. Emerging opportunities lie in the development of allogeneic therapies, which promise reduced costs and enhanced accessibility. Collaborations and partnerships with biotech firms to innovate and enhance therapy efficacy can provide a competitive edge. However, challenges such as high treatment costs, complexities in manufacturing processes, and stringent regulatory requirements can hinder growth. Additionally, logistical challenges, including the need for personalized treatment, also pose significant constraints. To overcome these obstacles, enhancing production technologies and focusing on cost-effective methods are crucial. There is a growing need for research in understanding tumor microenvironments and improving the specificity of T-cells to reduce unintended side effects. The market exudes a dynamic nature, characterized by rapid technological innovations, intense competition, and evolving regulatory landscapes. The best areas of innovation include developing next-generation T-cell therapies that can target a wider range of tumors and enhancing the safety profiles of existing therapies. By focusing on these areas, companies can seize opportunities to advance T-cell immunotherapy and enjoy significant growth and success in this rapidly evolving market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving T-Cell Immunotherapy Market

The T-Cell Immunotherapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing Prevalence of Cancer and Autoimmune Diseases
  • Use of Cell-Based Targeted Therapies
  • Increasing R&D Supporting T-cell Immunotherapy
• Market Restraints
  • High Cost of Treatment
• Market Opportunities
  • Commercialisation and Funding by Pharmaceutical Companies
  • Attractiveness of Off-the-Shelf Therapies
• Market Challenges
  • Neurologic Toxicities and Cytokine Release Syndrome

Porter's Five Forces: A Strategic Tool for Navigating the T-Cell Immunotherapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the T-Cell Immunotherapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the T-Cell Immunotherapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the T-Cell Immunotherapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the T-Cell Immunotherapy Market

A detailed market share analysis in the T-Cell Immunotherapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the T-Cell Immunotherapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the T-Cell Immunotherapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the T-Cell Immunotherapy Market

A strategic analysis of the T-Cell Immunotherapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the T-Cell Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Therapeutics PLC, Alaunos Therapeutics, Inc., Apac Biotech, Atara Biotherapeutics, Inc., Autolus Therapeutics PLC, bluebird bio, Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited, Cellectis SA, Chimera Bioengineering, Dendreon Pharmaceuticals LLC, Eureka Therapeutics, Inc., Gilead Sciences, Inc., Green Cross Corporation, Innovative Cellular Therapeutics, Iovance Biotherapeutics, Inc., LAVA Therapeutics N.V., Lyell Immunopharma, Inc., Neogene Therapeutics, Inc., NeoTX Therapeutics Ltd., Novartis AG, Oxford Vacmedix UK Limited, Poseida Therapeutics, Inc., TScan Therapeutics, Inc., and Xenetic Biosciences, Inc..

Market Segmentation & Coverage

This research report categorizes the T-Cell Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Mechanism Of Action, market is studied across Active Immunotherapy and Passive Immunotherapy.
• Based on Product Class, market is studied across Bispecific Antibodies, Cytokines, Monoclonal Antibodies, and Oncolytic Virus Therapy.
• Based on Type of Therapy, market is studied across CAR-T, TCR, and TIL.
• Based on Indication, market is studied across B-cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Prevalence of Cancer and Autoimmune Diseases
    • 5.1.1.2. Use of Cell-Based Targeted Therapies
    • 5.1.1.3. Increasing R&D Supporting T-cell Immunotherapy
  • 5.1.2. Restraints
    • 5.1.2.1. High Cost of Treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Commercialisation and Funding by Pharmaceutical Companies
    • 5.1.3.2. Attractiveness of Off-the-Shelf Therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Neurologic Toxicities and Cytokine Release Syndrome
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. T-Cell Immunotherapy Market, by Mechanism Of Action

• 6.1. Introduction
• 6.2. Active Immunotherapy
• 6.3. Passive Immunotherapy

7. T-Cell Immunotherapy Market, by Product Class

• 7.1. Introduction
• 7.2. Bispecific Antibodies
• 7.3. Cytokines
• 7.4. Monoclonal Antibodies
• 7.5. Oncolytic Virus Therapy

8. T-Cell Immunotherapy Market, by Type of Therapy

• 8.1. Introduction
• 8.2. CAR-T
• 8.3. TCR
• 8.4. TIL

9. T-Cell Immunotherapy Market, by Indication

• 9.1. Introduction
• 9.2. B-cell Malignancies
• 9.3. Liver Cancer
• 9.4. Prostate Cancer
• 9.5. Renal Cell Carcinoma

10. Americas T-Cell Immunotherapy Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific T-Cell Immunotherapy Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa T-Cell Immunotherapy Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adaptimmune Therapeutics PLC
• 2. Alaunos Therapeutics, Inc.
• 3. Apac Biotech
• 4. Atara Biotherapeutics, Inc.
• 5. Autolus Therapeutics PLC
• 6. bluebird bio, Inc.
• 7. Bristol-Myers Squibb Company
• 8. CARsgen Therapeutics Holdings Limited
• 9. Cellectis SA
• 10. Chimera Bioengineering
• 11. Dendreon Pharmaceuticals LLC
• 12. Eureka Therapeutics, Inc.
• 13. Gilead Sciences, Inc.
• 14. Green Cross Corporation
• 15. Innovative Cellular Therapeutics
• 16. Iovance Biotherapeutics, Inc.
• 17. LAVA Therapeutics N.V.
• 18. Lyell Immunopharma, Inc.
• 19. Neogene Therapeutics, Inc.
• 20. NeoTX Therapeutics Ltd.
• 21. Novartis AG
• 22. Oxford Vacmedix UK Limited
• 23. Poseida Therapeutics, Inc.
• 24. TScan Therapeutics, Inc.
• 25. Xenetic Biosciences, Inc.

LIST OF FIGURES

• FIGURE 1. T-CELL IMMUNOTHERAPY MARKET RESEARCH PROCESS
• FIGURE 2. T-CELL IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. T-CELL IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. T-CELL IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. T-CELL IMMUNOTHERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CAR-T, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TCR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TIL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 39. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 40. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 61. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 62. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 65. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 66. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 134. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 135. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 150. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 151. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 154. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 155. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 193. T-CELL IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023